News Releases

News releases related to ophthalmology

Information in this news release was current as of the original release date.

Otsuka Pharmaceutical's news releases are intended to provide information to the media. It may contain information about ethical drugs or products under development, however information contained in the news releases are not intended to constitute promotion, advertisement, or medical advice.

2025

News releases related to ophthalmology

Otsuka Enters into Licensing Agreement for Ophthalmic Gene Therapy Drug Candidate 4D-150 (Anti-VEGF agent) ‐ Acquires Exclusive Development and Commercialization Rights for Asia-Oceania Region, Including Japan, from 4DMT ‐

Otsuka collaborates with ShapeTX to develop novel AAV gene therapies for ocular diseases

Launch of a New Combination Ophthalmic Solution for the Treatment of Glaucoma and Ocular Hypertension, AILAMIDE® Combination Ophthalmic Suspension

Senju and Otsuka Launch a New Treatment for Glaucoma and Ocular Hypertension - AIBETA® Combination Ophthalmic Solution

Otsuka Supports "Light-Up in Green" Glaucoma Awareness Activities

Otsuka Launches a New Treatment for Glaucoma and Ocular Hypertension - Mikeluna® Combination Ophthalmic Solution in Japan

Otsuka Receives Approval in Japan for Mikeluna® Combination Ophthalmic Solution, a New Treatment for Glaucoma and Ocular Hypertension

Announcement of Co-promotion of New Glaucoma Treatment (PDF: 45.7 KB)

Announcement of Termination of Co-Development and Co-Commercialization Agreements with Acucela, Inc.

New Drug Application for Carteolol Hydrochloride/ Latanoprost, a Novel Combined Ophthalmic Solution, Submitted in Japan for the Treatment of Glaucoma and Ocular Hypertension

Acucela and Otsuka Pharmaceutical Announce Phase IIa Clinical Results of Emixustat Hydrochloride (ACU-4429) in Patients with Geographic Atrophy (GA) Associated with Dry Age-related Macular Degeneration (AMD) at ARVO 2013 Annual Meeting

Acucela and Otsuka Pharmaceutical Announce the Initiation of a Phase 3 Clinical Trial to Evaluate Rebamipide Ophthalmic Suspension in Patients with Dry Eye Syndrome

Mucosta® ophthalmic suspension UD2% releases on January 5, 2012

Phase III Study Results for Rebamipide Ophthalmic Suspension for Dry Eye Announced at ARVO 2011

Otsuka Pharmaceutical Files for Regulatory Approval in Japan for Mucosta® Ophthalmic Suspension for Dry Eye

Otsuka Pharmaceutical and Acucela Enter New Co-Development and Co-Promotion Agreement for OPA-6566 for Glaucoma

Otsuka Pharmaceutical and Acucela Receive FDA Fast Track Designation for ACU-4429 in Patients with Dry AMD Novel, Oral Therapy in Phase 2 Clinical Trial for Dry AMD, A Leading Cause of Blindness in People Over Age 50

Acucela and Otsuka Pharmaceutical Enter Co-Development Agreement for ACU-4429 in Dry Age Related Macular Degeneration

Acucela and Otsuka Pharmaceutical Enter Co-Development Agreement for Rebamipide Ophthalmic Suspension for Dry Eye

Otsuka collaborates with Shape^TX to develop novel AAV gene therapies for ocular diseases

Launch of a New Combination Ophthalmic Solution for the Treatment of Glaucoma and Ocular Hypertension, AILAMIDE^® Combination Ophthalmic Suspension

Senju and Otsuka Launch a New Treatment for Glaucoma and Ocular Hypertension - AIBETA^® Combination Ophthalmic Solution

Otsuka Launches a New Treatment for Glaucoma and Ocular Hypertension - Mikeluna^® Combination Ophthalmic Solution in Japan

Otsuka Receives Approval in Japan for Mikeluna^® Combination Ophthalmic Solution, a New Treatment for Glaucoma and Ocular Hypertension

Mucosta^® ophthalmic suspension UD2% releases on January 5, 2012

Otsuka Pharmaceutical Files for Regulatory Approval in Japan for Mucosta^® Ophthalmic Suspension for Dry Eye